Generex Biotechnology Corp’s (OTCMKTS:GNBT) subsidiary NuGenerex Immuno-Oncology has announced the submission of a response to the FDA’s comments on a Pre-IND Written Response.
NuGenerex Immuno-Oncology responds to FDA’s comments Ii-Key vaccine
The response package offers important information requested by the FDA, including Li-Key epitope sequences, picked based on the ex-vivo blood screening program. It also includes the transgenic mouse immunogenicity study results showing vaccine-specific antibody production and GMP manufacturing information for Ii-Key-SARS-CoV-2 epitopes in the vaccine. There is also a revised protocol incorporating FDA’s requests and comments.
The company has previously reported ex-vivo blood screening program results, which enabled the selection of Ii-Key-SARS-CoV-2 epitopes from membrane and spike proteins based upon T-cell activation profiles. Notably, the company tested the five Ii-Key epitopes in a mouse model engineered with a human immune system part.
NuGenerx Immuno-Oncology CEO Joe Moscato said that the company has made considerable progress in Ii-Key SARS-CoV-2 vaccines. He said that a year a goo chose to use the Ii-Key tech to offer a targeted, safe, and specific Complete Vaccine™ that creates neutralizing antibodies and T-Cell activation for enhanced immune memory.
NuGenerex creating COVID-19 vaccine for pediatric and pregnant women
Generex Biotechnology and NuGenerex Immuno-Oncology have announced a partnership with Last Chance for Children’s Mission to help save the lives of children across the globe. With the COVID-19 pandemic, the company’s efforts are on helping eradicate the virus by vaccinating children in need. The pandemic has disrupted children’s lives, and so far, there is no approved vaccine for children under 12 or pregnant women.
As a result, NuGenerex’s Ii-Key COVID-19 vaccine could be vital in protecting against the virus. The Ii-Key vaccine is based on amino acid sequences mimicking the COVID-19 spike and membrane proteins. It selectively regulates immune responses targeting the SARS-CoV-2 virus without genetic material like most vaccines that use DNA and RNA vectors.
NuGenerex is focusing on creating a safe and effective COVID-19 vaccine for pregnant women and pediatric populations, populations with significant unmet needs in the race for the COVID-19 vaccine.
THC Biomed Intl Ltd (OTCMKTS: THCBF) Amends its Health Canada Licence to Include Three Strata Units at its Acland Road Location
Post Views: 5 It took only a year for THC Biomed Intl Ltd (OTCMKTS: THCBF) to obtain a rare license...
Tetra Bio-Pharma Inc. (OTCMKTS: TBPMF) Obtains an Approval of the Proposed Protocol Modifications to Accelerate the REBORN Study
Post Views: 37 Clinical trials are an essential component of any drug discovery and development program. Innovative research initiatives are...
The Appointment of Philip Goldberg, Formerly of Green Leaf Medical, to the Board of Directors of Columbia Care Inc. (OTCMKTS: CCHWF)
Post Views: 6 The growing acceptance and recognition of marijuana for its medical purposes has made an impact on cannabis...
Surna Inc, (OTCMKTS: SRNA) Expands its Line of Curated HVACD Family Products with the Introduction of EnviroPro™ Air Handler
Post Views: 6 The cultivation of cannabis comes with a myriad of challenges. Designing cultivation facilities and deploying the systems...
Mydecine Innovations Group Inc. (OTCMKTS: MYCOF) Supports the Launch of Version 2.0, a Digital Health Platform by its Subsidiary Mindleap Health
Post Views: 3 The COVID 19 pandemic took the world by storm and has left hundreds of thousands of people...
HempMeds Latin American Operations, a subsidiary of Medical Marijuana, Inc. (OTCMKTS: MJNA), Announces a 12% Revenue Increase in June 2021 Compared to June 2020
Post Views: 18 What comes to mind when you hear the words, “Medical marijuana?” It is seemingly regarded as the...